American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Investing

Is it safe to buy the Tempus AI stock dip now?

by admin April 9, 2025
April 9, 2025
Is it safe to buy the Tempus AI stock dip now?

Tempus AI stock price remains in a deep bear market as investors worry that the hype that drove it to a record high was ending. The TEM stock initially peaked at $91.40 in February, and has now plunged to a low of $37.2, meaning that it has dropped by 60%. So, is it safe to buy the dip or wait for it to fall further?

Why Tempus AI has plunged

Tempus AI is one of the top American companies in the artificial intelligence space. Its goal is to help all players in the medical industry to simplify their operations, boost innovation, reduce costs, and grow sales. 

The Tempus Platform comprises three key components, including Tempus Hub, Tempus Lens, and Tempus Lens. Tempus Hub is a platform that streamlines providers’ workflows and gives access to patient insights. 

Lens is a platform that helps researchers to find, access, and analyze multimodal data and uncover crucial insights. Next is a tool that helps providers deliver the next steps in a patient’s care data. 

Analysts believe that the medical industry is one of the best use cases for the artificial intelligence industry. It is primarily useful in research since large AI models can analyze vast data within minutes. 

AI technology is also useful in areas like diagnostics and treatment. It generates results like DNA, RNA, clinical imaging, clinical EMR, and epigenetics. 

Tempus AI business has grown rapidly in the past few years as more companies have embraced its technology. It is now used by some of the top companies in the healthcare industry like AstraZeneca, GlaxoSmithKline, BioNTech, Rain Oncology, and Kronos Bio.

TEM business is growing

The most recent results showed that Tempus AI business was growing. Its quarterly revenue rose by 35.8% YoY in the last quarter of 2024 to $200.7 million. Most of this revenue came from its genomics segment, which made over $120.4 million. The data and services segment rose to $80.2 million.

Most importantly, the company is making more strides to become profitable. Its gross profit rose by almost 50% to $122.1 million, while the net loss improved to $13 million, up from $50 million a quarter earlier. 

The annual revenue jumped by 30% to $693 million, with its genomics business making over $451.7 million. The data and service segment rose to $241 million.

Analysts are optimistic that the Tempus AI business will continue doing well this year. The average estimate is that its first quarter revenue will be $248.8 million. Its annual revenue will be $1.24 billion, followed by $1.55 billion next year. The company will break even next year. 

Analysts are highly bullish on the TEM stock, with the average estimate being $64.22, higher than the current $37.23.

Read more: Cathie Wood bets big on Tempus AI: Is it the next big thing in health-tech?

Tempus AI stock price analysis

TEM stock chart | Source: TradingView

The daily chart shows that the TEM share price has crashed in the past few weeks, moving from the year-to-date high of $91.40 to a low of $37.23. This price is along the ascending trendline that connects the lowest swing since June last year. 

The stock has moved below the 25-day moving average. It has also moved slightly below the bottom of the trading range at $37.5. The Relative Strength Index (RSI) also dropped below the middle line at 50.

Therefore, the stock will likely continue falling as sellers target the key target at $25, the strong pivot, and reverse at $25. In the future, however, Tempus AI stock price will likely bounce back, and possibly retest its all-time high.

The post Is it safe to buy the Tempus AI stock dip now? appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Lululemom stock faces a double whammy: $130 target in sight
next post
Nio stock price resilient to trade war, yet crash to $1.12 likely

Related Posts

NextSource Materials

May 30, 2024

Here’s why the ZIM Integrated stock could slip...

November 18, 2024

Critical Metals Corp Completes Stage 1 Investment for...

July 27, 2024

Edison Lithium: Transitioning to Sodium-ion Battery Technology

March 28, 2024

Apollo Global vs KKR: Which is the better...

October 12, 2024

SNX to Follow up 1270 g/t Silver Intercept...

May 21, 2024

Top 5 Manganese Reserves by Country (Updated 2024)

May 28, 2024

Top 3 ways to boost the languishing Pi...

May 27, 2025

Byron King: Will Gold Miners’ Q2 Results Catch...

July 15, 2024

Changes to the Board & Company Update

February 20, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Why India’s gold demand is expected to dip this festive season

      September 15, 2025
    • Oil jumps 2% as OPEC agree to smaller output hike for October, sanction threats looms

      September 8, 2025
    • Weekly recap: tech titans woo Trump, Xi’s political theatre, Starmer’s reshuffle

      September 7, 2025
    • Trump reaffirms backing for Robert Kennedy amid vaccine policy turmoil

      September 7, 2025
    • South Korean president promises aid to citizens held in US immigration raid

      September 7, 2025

    Categories

    • Business (3,964)
    • Investing (2,871)
    • Latest News (2,059)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved